WO2018120920A1 - 一种苯磺顺阿曲库铵冻干粉针制剂 - Google Patents

一种苯磺顺阿曲库铵冻干粉针制剂 Download PDF

Info

Publication number
WO2018120920A1
WO2018120920A1 PCT/CN2017/101871 CN2017101871W WO2018120920A1 WO 2018120920 A1 WO2018120920 A1 WO 2018120920A1 CN 2017101871 W CN2017101871 W CN 2017101871W WO 2018120920 A1 WO2018120920 A1 WO 2018120920A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
lyophilized powder
lyophilized
powder preparation
atracurium
Prior art date
Application number
PCT/CN2017/101871
Other languages
English (en)
French (fr)
Inventor
王坚
杜芳
王小镒
甄国艳
缪敏
Original Assignee
上药东英（江苏）药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上药东英（江苏）药业有限公司 filed Critical 上药东英（江苏）药业有限公司
Publication of WO2018120920A1 publication Critical patent/WO2018120920A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the invention belongs to the field of chemical pharmacy, and particularly relates to a benzenesulfonate atracurium ammonium composition for injection and a preparation method thereof, in particular to a phenylsulfasuccinic acid lyophilized powder preparation and a preparation method thereof.
  • Cistracurium besilate is a novel non-depolarizing muscle relaxant of benzylisoquinoline, a kind of ten isomers of atracurium, and is the latest generation of muscle relaxant. It has a muscle relaxation effect and a metabolic process similar to atracurium benzenesulfonate. Benzosulfas atracurium has the characteristics of metabolism through non-hepatic and non-renal pathways and cardiovascular stability. The muscle relaxant is 3 times stronger than atracurium, and does not release histamine. The cardiovascular response is small, which is ideal. Medium-aged non-depolarizing muscle relaxants.
  • benzenesulfasuccinic acid is mainly used for general anesthesia, and can be widely used in tracheal intubation, liver and kidney dysfunction, cardiovascular surgery and elderly and pediatric patients. Since the drug was first marketed in the UK in 1996, it has gradually replaced vecuronium bromide and atracurium in foreign countries, becoming the mainstream of clinical muscle relaxants. However, the stability of sulfonate cis-atracurium in aqueous solution is poor, so the clinical application of sulfonate cis-atracurium is limited to some extent.
  • Lipid system refers to a closed vesicle composed of a phospholipid as a membrane and an additive, and has a bilayer structure. Due to its structure similar to biofilm, it can encapsulate water-soluble and fat-soluble drugs, improve drug stability, reduce drug dosage, reduce toxicity, reduce allergic reactions and immune reactions, change the distribution of drugs in the body, and can be targeted.
  • the advantages of medicine and so on have been widely noted and in-depth research.
  • the invention applies the liposome preparation technology to the phenylsulfasin atracurium lyophilized powder injection, which greatly improves the storage stability of the sulfonate cis-atracurium ammonium preparation, and the preparation method is convenient to operate, the lyophilization process is simple, The quality is controllable, safe and reliable for human body, suitable for clinical application.
  • the invention provides a phenylsulfonium sulbactam lyophilized powder preparation prepared by the following components by weight: 1-5 parts of sulfasuccinamide, dimyristoyl phosphatidylcholine 10 - 40 parts, 5-15 parts of sodium deoxycholate, 0.15-0.50 parts of antioxidant, 0.5-1 part of polyvinylpyrrolidone, and 5-25 parts of lyophilized support.
  • the preparation is prepared from the following components by weight: 1 part of sulfasuccinamide, 10 parts of dimyristoyl phosphatidylcholine, 5 parts of sodium deoxycholate, and the like. 0.15 parts of oxygen agent, 0.5 part of polyvinylpyrrolidone, and 8 parts of lyophilized support.
  • the preparation is prepared from the following components by weight: 3 parts of sulfonate cis-atracurium, 20 parts of dimyristoyl phosphatidylcholine, 10 parts of sodium deoxycholate, and anti- 0.3 part of oxygen agent, 0.8 part of polyvinylpyrrolidone, and 16 parts of lyophilized support.
  • the formulation is made up of the following parts by weight: sulfonate cis-atracurium 5 40 parts of dimyristoyl phosphatidylcholine, 15 parts of sodium deoxycholate, 0.45 parts of antioxidant, 1 part of polyvinylpyrrolidone, and 24 parts of lyophilized support.
  • the antioxidant is a combination of sodium thiosulfate and vitamin E, and the ratio of the two is 2:1.
  • the lyophilized support agent is selected from one or more of the group consisting of mannitol, lactose, glucose, sucrose, sorbitol, sodium chloride, and glycine.
  • the lyophilized support agent is a combination of sodium chloride, mannitol and glucose, and the mass ratio of the three is 1:2:1.
  • the preparation is prepared from the following components by weight: 1 part of sulfonate cis-atracurium, 10 parts of dimyristoyl phosphatidylcholine, 5 parts of sodium deoxycholate, and the like.
  • Oxygen agent 0.15 parts, polyvinylpyrrolidone 0.5 parts, lyophilized support agent 8 parts; antioxidant is a combination of sodium thiosulfate and vitamin E, the ratio of the two is 2:1; lyophilized support agent is sodium chloride
  • the combination of mannitol and glucose has a mass ratio of 1:2:1.
  • the preparation is prepared from the following components by weight: 3 parts of sulfonate cis-atracurium, 20 parts of dimyristoyl phosphatidylcholine, 10 parts of sodium deoxycholate, and anti- Oxygen agent 0.3 parts, polyvinylpyrrolidone 0.8 parts, lyophilized support agent 16 parts; antioxidant is a combination of sodium thiosulfate and vitamin E, the ratio of the two is 2:1; lyophilized support agent is sodium chloride The combination of mannitol and glucose has a mass ratio of 1:2:1.
  • the preparation is prepared from the following components by weight: 5 parts of sulfonate cis-atracurium, 40 parts of dimyristoyl phosphatidylcholine, 15 parts of sodium deoxycholate, and anti- 0.45 parts of oxygen, 1 part of polyvinylpyrrolidone, 24 parts of lyophilized support; antioxidant is a combination of sodium thiosulfate and vitamin E, the ratio of the two is 2:1; the lyophilized support is sodium chloride The combination of mannitol and glucose has a mass ratio of 1:2:1.
  • Another aspect of the invention relates to a method for preparing a phenylsulfonium cis-curium lyophilized powder preparation, which comprises the steps of: (1) dimyristoyl phosphatidylcholine, sodium deoxycholate, and an antioxidant; , the polyvinylpyrrolidone is dissolved in an organic solvent, and uniformly mixed, and then the formed solution is removed under reduced pressure to remove the organic solvent to prepare a lipid film;
  • step (3) Weighing benzenesulfonate atracurium, dissolved in water for injection, sterilized by microfiltration membrane filtration, added to the blank liposome prepared in step (2), and then added to freeze-dried support The agent is evenly mixed and left for 10-30 minutes, then sterilized by filtration through a microporous membrane, filled in a vial, and lyophilized to obtain.
  • the antioxidant is a combination of sodium thiosulfate and vitamin E, and the ratio of the two is 2:1.
  • the lyophilized support agent is selected from the group consisting of mannitol, lactose, glucose, and sugar cane One or more of sugar, sorbitol, sodium chloride, and glycine.
  • the lyophilized support agent is a combination of sodium chloride, mannitol and glucose, and the mass ratio of the three is 1:2:1.
  • the organic solvent is selected from the group consisting of one or more of ethanol, acetone, isopropanol, and t-butanol.
  • the buffer solution is selected from one of a phosphate buffer solution, a citrate buffer solution, a carbonate buffer solution, a borate buffer solution, and an acetate buffer solution.
  • a third aspect of the invention relates to the use of a phenylsulfonium cis-atracurium lyophilized powder preparation for the preparation of a muscle relaxant anesthetic.
  • parts by weight can be converted into arbitrary weight units.
  • phenylsulfasycontracurium lyophilized powder preparation of the present invention is further illustrated below in conjunction with specific examples.
  • step (3) Weighing benzenesulfonate atracurium, dissolved in water for injection, sterilized by microfiltration membrane filtration, added to the blank liposome prepared in step (2), and then added sodium chloride , mannitol and glucose, mixed evenly, placed for 10-30 minutes, then filtered through a microporous membrane filter, filled in a vial, lyophilized, that is.
  • step (3) Weighing benzenesulfonate atracurium, dissolved in water for injection, sterilized by microfiltration membrane filtration, added to the blank liposome prepared in step (2), and then added sodium chloride , mannitol and glucose, mixed evenly, placed for 10-30 minutes, then filtered through a microporous membrane filter, filled in a vial, lyophilized, that is.
  • step (3) Weighing benzenesulfonate atracurium, dissolved in water for injection, sterilized by microfiltration membrane filtration, added to the blank liposome prepared in step (2), and then added sodium chloride , mannitol and glucose, mixed evenly, placed for 10-30 minutes, then filtered through a microporous membrane filter, filled in a vial, lyophilized, that is.
  • Example 3 99.95% Comparative example 1 91.34% Comparative example 2 94.57% Comparative example 3 94.86% Comparative example 4 95.43% Comparative example 5 94.12% Comparative example 6 95.37% Comparative example 7 96.82% Comparative example 8 94.71%
  • Table 1 show that the phenylsulfonium sulbactam lyophilized powder preparation prepared in Example 1-3 of the present invention has high stability, and is placed at 40 ⁇ 2° C. and RH 75% accelerated condition for 30 days.
  • the content of sulfa-atracurium was not changed substantially, and the content of benzenesulfasuccinate was significantly lower in Comparative Examples 1-8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种可用于静脉给药的苯磺顺阿曲库铵冻干粉针制剂，由以下重量份的成分制成：苯磺顺阿曲库铵1-5份、二肉豆蔻酰磷脂酰胆碱10-40份、脱氧胆酸钠5-15份、抗氧剂0.15-0.50份、聚乙烯吡咯烷酮0.5-1份、冻干支持剂5-25份。

Description

一种苯磺顺阿曲库铵冻干粉针制剂 技术领域
本发明属于化学制药领域，具体涉及一种注射用苯磺顺阿曲库铵组合物及其制备方法，尤其是涉及一种苯磺顺阿曲库铵冻干粉针制剂及其制备方法。
背景技术
苯磺顺阿曲库铵(cisatracurium besilate)是新型苄异喹啉类中效非去极化肌松药，是阿曲库铵十种同分异构体的一种，是最新一代肌松剂，具有与苯磺酸阿曲库铵相似的肌松效应及代谢过程。苯磺顺阿曲库铵具有通过非肝非肾途径代谢的特点和心血管稳定性，肌松作用比阿曲库铵作用强3倍，且不释放组胺，心血管反应小，是较为理想的中时效非去极化肌松药。与目前临床主要肌松麻醉药比较，苯磺顺阿曲库铵主要适用于全身麻醉，并能广泛应用在气管插管、肝肾功能障碍、心血管手术及老年和儿科病人。该药自1996年在英国首次上市后，国外已逐渐代替维库溴铵和阿曲库铵，成为临床肌松药的主流。但是苯磺顺阿曲库铵在水溶液中稳定性较差，因此在一定程度上限制了苯磺顺阿曲库铵的临床应用。
脂质体系指由磷脂为膜材及附加剂组成的封闭囊泡，具有双分子层结构。由于其结构类似生物膜，可包封水溶性和脂溶性药物，具有提高药物稳定性，减少药物用量，降低毒性，减轻变态反应和免疫反应，改变药物在体内的分布，并能靶向性释药等优点而得到广泛注意和深入研究。
发明内容
本发明将脂质体制备技术应用于苯磺顺阿曲库铵冻干粉针剂，极大地提高了苯磺顺阿曲库铵制剂的贮存稳定性，并且制备方法操作方便、冻干工艺简单、质量可控，对人体安全可靠，适于临床应用。
本发明提供一种苯磺顺阿曲库铵冻干粉针制剂，该制剂由以下重量份的成分制成：苯磺顺阿曲库铵1-5份、二肉豆蔻酰磷脂酰胆碱10-40份、脱氧胆酸钠5-15份、抗氧剂0.15-0.50份、聚乙烯吡咯烷酮0.5-1份、冻干支持剂5-25份。
在本发明一个优选是实施方式中，该制剂由以下重量份的成分制成：苯磺顺阿曲库铵1份、二肉豆蔻酰磷脂酰胆碱10份、脱氧胆酸钠5份、抗氧剂0.15份、聚乙烯吡咯烷酮0.5份、冻干支持剂8份。
在本发明一个优选是实施方式中，该制剂由以下重量份的成分制成：苯磺顺阿曲库铵3份、二肉豆蔻酰磷脂酰胆碱20份、脱氧胆酸钠10份、抗氧剂0.3份、聚乙烯吡咯烷酮0.8份、冻干支持剂16份。
在本发明一个优选是实施方式中，该制剂由以下重量份的成分制成：苯磺顺阿曲库铵5 份、二肉豆蔻酰磷脂酰胆碱40份、脱氧胆酸钠15份、抗氧剂0.45份、聚乙烯吡咯烷酮1份、冻干支持剂24份。
在本发明一个具体的实施方式中，其中所述的抗氧剂为硫代硫酸钠和维生素E的组合，二者的配比为2：1。
在本发明一个具体的实施方式中，其中所述冻干支持剂选自甘露醇、乳糖、葡萄糖、蔗糖、山梨醇、氯化钠、甘氨酸的一种或多种。
在本发明一个优选的实施方式中，所述的冻干支持剂为氯化钠、甘露醇和葡萄糖的组合，三者的质量比为1:2:1。
在本发明一个优选的实施方式中，该制剂由以下重量份的成分制成：苯磺顺阿曲库铵1份、二肉豆蔻酰磷脂酰胆碱10份、脱氧胆酸钠5份、抗氧剂0.15份、聚乙烯吡咯烷酮0.5份、冻干支持剂8份；抗氧剂为硫代硫酸钠和维生素E的组合，二者的配比为2：1；冻干支持剂为氯化钠、甘露醇和葡萄糖的组合，三者的质量比为1:2:1。
在本发明一个优选是实施方式中，该制剂由以下重量份的成分制成：苯磺顺阿曲库铵3份、二肉豆蔻酰磷脂酰胆碱20份、脱氧胆酸钠10份、抗氧剂0.3份、聚乙烯吡咯烷酮0.8份、冻干支持剂16份；抗氧剂为硫代硫酸钠和维生素E的组合，二者的配比为2：1；冻干支持剂为氯化钠、甘露醇和葡萄糖的组合，三者的质量比为1:2:1。
在本发明一个优选是实施方式中，该制剂由以下重量份的成分制成：苯磺顺阿曲库铵5份、二肉豆蔻酰磷脂酰胆碱40份、脱氧胆酸钠15份、抗氧剂0.45份、聚乙烯吡咯烷酮1份、冻干支持剂24份；抗氧剂为硫代硫酸钠和维生素E的组合，二者的配比为2：1；冻干支持剂为氯化钠、甘露醇和葡萄糖的组合，三者的质量比为1:2:1。
本发明另一方面涉及所述的苯磺顺阿曲库铵冻干粉针制剂的制备方法，制备步骤包括：(1)将二肉豆蔻酰磷脂酰胆碱、脱氧胆酸钠、抗氧剂、聚乙烯吡咯烷酮溶于有机溶剂中，混合均匀，然后将形成的溶液减压脱除有机溶剂，制备脂质膜；
(2)配置pH为3-4的缓冲盐溶液，将缓冲溶液加入到步骤(1)中制备的脂质膜中，待脂质膜完全水化后，用均浆设备制备空白脂质体，备用；
(3)称取苯磺顺阿曲库铵，溶于注射用水中，经微孔滤膜过滤除菌后，加入到步骤(2)中制得的空白脂质体中，再加入冻干支持剂，混合均匀，放置10-30分钟，然后经微孔滤膜过滤除菌，灌装于西林瓶中，冷冻干燥，即得。
在本发明一个具体的实施方式中，其中所述的抗氧剂为硫代硫酸钠和维生素E的组合，二者的配比为2：1。
在本发明一个具体的实施方式中，其中所述冻干支持剂选自甘露醇、乳糖、葡萄糖、蔗 糖、山梨醇、氯化钠、甘氨酸的一种或多种。
在本发明一个优选的实施方式中，所述的冻干支持剂为氯化钠、甘露醇和葡萄糖的组合，三者的质量比为1:2:1。
在本发明一个具体的实施方式中，有机溶剂选自乙醇、丙酮、异丙醇、叔丁醇中的一种或多种的组合。
在本发明一个具体的实施方式中，所述缓冲溶液选自磷酸盐缓冲液、枸橼酸盐缓冲液、碳酸盐缓冲液、硼酸盐缓冲液、醋酸盐缓冲液中的一种或几种。
本发明第三方面涉及述注苯磺顺阿曲库铵冻干粉针制剂在制备肌松麻醉药中的应用。
本发明中重量份可以转换成任意的重量单位。
下面结合具体的实施例进一步阐述本发明的苯磺顺阿曲库铵冻干粉针制剂。
具体实施方式
实施例1：
Figure PCTCN2017101871-appb-000001
(1)称取处方量二肉豆蔻酰磷脂酰胆碱、脱氧胆酸钠、硫代硫酸钠、维生素E、聚乙烯吡咯烷酮溶于乙醇中，混合均匀，形成脂质体溶液，将脂质体溶液于薄膜蒸发器上，减压脱出乙醇，制得脂质膜。
(2)配置pH为3.5的磷酸盐缓冲液，将缓冲溶液加入到步骤(1)中制备的脂质膜中，待脂质膜完全水化后，用均浆设备制备空白脂质体，备用；
(3)称取苯磺顺阿曲库铵，溶于注射用水中，经微孔滤膜过滤除菌后，加入到步骤(2)中制得的空白脂质体中，再加入氯化钠、甘露醇和葡萄糖，混合均匀，放置10-30分钟，然后经微孔滤膜过滤除菌，灌装于西林瓶中，冷冻干燥，即得。
实施例2：
Figure PCTCN2017101871-appb-000002
Figure PCTCN2017101871-appb-000003
(1)称取处方量二肉豆蔻酰磷脂酰胆碱、脱氧胆酸钠、硫代硫酸钠、维生素E、聚乙烯吡咯烷酮溶于乙醇中，混合均匀，形成脂质体溶液，将脂质体溶液于薄膜蒸发器上，减压脱出乙醇，制得脂质膜。
(2)配置pH为3.8的磷酸盐缓冲液，将缓冲溶液加入到步骤(1)中制备的脂质膜中，待脂质膜完全水化后，用均浆设备制备空白脂质体，备用；
(3)称取苯磺顺阿曲库铵，溶于注射用水中，经微孔滤膜过滤除菌后，加入到步骤(2)中制得的空白脂质体中，再加入氯化钠、甘露醇和葡萄糖，混合均匀，放置10-30分钟，然后经微孔滤膜过滤除菌，灌装于西林瓶中，冷冻干燥，即得。
实施例3：
Figure PCTCN2017101871-appb-000004
(1)称取处方量二肉豆蔻酰磷脂酰胆碱、脱氧胆酸钠、硫代硫酸钠、维生素E、聚乙烯吡咯烷酮溶于乙醇中，混合均匀，形成脂质体溶液，将脂质体溶液于薄膜蒸发器上，减压脱出乙醇，制得脂质膜。
(2)配置pH为4.0的磷酸盐缓冲液，将缓冲溶液加入到步骤(1)中制备的脂质膜中，待脂质膜完全水化后，用均浆设备制备空白脂质体，备用；
(3)称取苯磺顺阿曲库铵，溶于注射用水中，经微孔滤膜过滤除菌后，加入到步骤(2)中制得的空白脂质体中，再加入氯化钠、甘露醇和葡萄糖，混合均匀，放置10-30分钟，然后经微孔滤膜过滤除菌，灌装于西林瓶中，冷冻干燥，即得。
对比例1：(大豆卵磷脂替换二肉豆蔻酰磷脂酰胆碱)
Figure PCTCN2017101871-appb-000005
其他同实施例1。
对比例2：(胆固醇替换脱氧胆酸钠)
Figure PCTCN2017101871-appb-000006
其他同实施例1。
对比例3：(省略硫代硫酸钠)
Figure PCTCN2017101871-appb-000007
Figure PCTCN2017101871-appb-000008
其他同实施例1。
对比例4：(省略维生素E)
Figure PCTCN2017101871-appb-000009
其他同实施例1。
对比例5：(省略聚乙烯吡咯烷酮)
Figure PCTCN2017101871-appb-000010
其他同实施例1。
对比例6：(省略氯化钠)
Figure PCTCN2017101871-appb-000011
Figure PCTCN2017101871-appb-000012
其他同实施例1。
对比例7：(省略甘露醇)
Figure PCTCN2017101871-appb-000013
其他同实施例1。
对比例8：(省略葡萄糖)
Figure PCTCN2017101871-appb-000014
其他同实施例1。
实施例4稳定性实验
将本发明实施例1-3和对比例1-8制备的冻干制剂，在40±2℃、RH75％加速条件下放置30天，测定苯磺顺阿曲库铵含量变化，进行稳定性考察，结果如下：
表1苯磺顺阿曲库铵冻干粉针剂的稳定性
组别 苯磺顺阿曲库铵含量(％)
实施例1 99.97％
实施例2 99.96％
实施例3 99.95％
对比例1 91.34％
对比例2 94.57％
对比例3 94.86％
对比例4 95.43％
对比例5 94.12％
对比例6 95.37％
对比例7 96.82％
对比例8 94.71％
表1的结果表明，本发明实施例1-3制备得到的苯磺顺阿曲库铵冻干粉针制剂具有较高的稳定性，在40±2℃、RH75％加速条件下放置30天苯磺顺阿曲库铵的含量基本不会发生改变，而对比例1-8中苯磺顺阿曲库铵的含量会显著降低。

Claims (8)

  1. 一种苯磺顺阿曲库铵冻干粉针制剂，其特征在于，该制剂由以下重量份的成分制成：苯磺顺阿曲库铵1-5份、二肉豆蔻酰磷脂酰胆碱10-40份、脱氧胆酸钠5-15份、抗氧剂0.15-0.50份、聚乙烯吡咯烷酮0.5-1份、冻干支持剂5-25份。
  2. 根据权利要求1所述的苯磺顺阿曲库铵冻干粉针制剂，其中所述的抗氧剂为硫代硫酸钠和维生素E的组合，二者的配比为2：1。
  3. 根据权利要求1所述的苯磺顺阿曲库铵冻干粉针制剂，其中所述冻干支持剂选自甘露醇、乳糖、葡萄糖、蔗糖、山梨醇、氯化钠、甘氨酸的一种或多种。
  4. 根据权利要求3所述的苯磺顺阿曲库铵冻干粉针制剂，其特征在于所述的冻干支持剂为氯化钠、甘露醇和葡萄糖的组合，三者的质量比为1:2:1。
  5. 权利要求1-4任一项所述的苯磺顺阿曲库铵冻干粉针制剂的制备方法，制备步骤包括：
    (1)将二肉豆蔻酰磷脂酰胆碱、脱氧胆酸钠、抗氧剂、聚乙烯吡咯烷酮溶于有机溶剂中，混合均匀，然后将形成的溶液减压脱除有机溶剂，制备脂质膜；
    (2)配置pH为3-4的缓冲盐溶液，将缓冲溶液加入到步骤(1)中制备的脂质膜中，待脂质膜完全水化后，用均浆设备制备空白脂质体，备用；
    (3)称取苯磺顺阿曲库铵，溶于注射用水中，经微孔滤膜过滤除菌后，加入到步骤(2)中制得的空白脂质体中，再加入冻干支持剂，混合均匀，放置10-30分钟，然后经微孔滤膜过滤除菌，灌装于西林瓶中，冷冻干燥，即得。
  6. 根据权利要求5所述的苯磺顺阿曲库铵冻干粉针制剂的制备方法，其特征在于有机溶剂选自乙醇、丙酮、异丙醇、叔丁醇中的一种或多种的组合。
  7. 根据权利要求5所述的苯磺顺阿曲库铵冻干粉针制剂的制备方法，所述缓冲溶液选自磷酸盐缓冲液、枸橼酸盐缓冲液、碳酸盐缓冲液、硼酸盐缓冲液、醋酸盐缓冲液中的一种或几种。
  8. 如权利要求1-4任一所述注苯磺顺阿曲库铵冻干粉针制剂在制备肌松麻醉药中的应用。
PCT/CN2017/101871 2016-12-26 2017-09-15 一种苯磺顺阿曲库铵冻干粉针制剂 WO2018120920A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611218033.9 2016-12-26
CN201611218033.9A CN106619544A (zh) 2016-12-26 2016-12-26 一种苯磺顺阿曲库铵冻干粉针制剂

Publications (1)

Publication Number Publication Date
WO2018120920A1 true WO2018120920A1 (zh) 2018-07-05

Family

ID=58826922

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/101871 WO2018120920A1 (zh) 2016-12-26 2017-09-15 一种苯磺顺阿曲库铵冻干粉针制剂

Country Status (2)

Country Link
CN (1) CN106619544A (zh)
WO (1) WO2018120920A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106619544A (zh) * 2016-12-26 2017-05-10 上药东英（江苏）药业有限公司 一种苯磺顺阿曲库铵冻干粉针制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101822669A (zh) * 2010-04-23 2010-09-08 海南美兰史克制药有限公司 一种阿莫西林钠舒巴坦钠药物组合物脂质体注射剂
CN105919950A (zh) * 2016-04-22 2016-09-07 上药东英（江苏）药业有限公司 一种苯磺顺阿曲库铵冻干粉针剂及其制备方法与应用
CN106619544A (zh) * 2016-12-26 2017-05-10 上药东英（江苏）药业有限公司 一种苯磺顺阿曲库铵冻干粉针制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101530393B (zh) * 2009-04-07 2010-10-13 王明 一种克林霉素磷酸酯脂质体冻干制剂
CN102579351B (zh) * 2012-03-23 2013-04-10 浙江磐谷药源有限公司 注射用美洛西林钠脂质体及制备方法
GB201211153D0 (en) * 2012-06-22 2012-08-08 Farmhispania Pharmaceutical compositions
CN104434822B (zh) * 2014-12-12 2017-06-06 海南先通药业有限公司 一种注射用苯磺顺阿曲库铵组合物及其制备方法与应用
CN104983694B (zh) * 2015-06-01 2018-05-04 上药东英（江苏）药业有限公司 25℃贮存运输使用的注射用苯磺顺阿曲库铵生产工艺
CN105078909B (zh) * 2015-09-18 2020-10-09 江苏盈科生物制药有限公司 一种注射用苯磺顺阿曲库铵冷冻干燥组合物及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101822669A (zh) * 2010-04-23 2010-09-08 海南美兰史克制药有限公司 一种阿莫西林钠舒巴坦钠药物组合物脂质体注射剂
CN105919950A (zh) * 2016-04-22 2016-09-07 上药东英（江苏）药业有限公司 一种苯磺顺阿曲库铵冻干粉针剂及其制备方法与应用
CN106619544A (zh) * 2016-12-26 2017-05-10 上药东英（江苏）药业有限公司 一种苯磺顺阿曲库铵冻干粉针制剂

Also Published As

Publication number Publication date
CN106619544A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
KR100658436B1 (ko) 아데노실코발라민 함유 피부질환 치료용 외용제 조성물
EP3505161B1 (en) Sublingual pharmaceutical composition of edaravone and (+)-2-borneol
CN1907291A (zh) 一种纳米七叶皂苷注射制剂及其制备方法
CN105078909B (zh) 一种注射用苯磺顺阿曲库铵冷冻干燥组合物及其制备方法
CN101401791A (zh) 噻吗洛尔脂质体及其制备方法
CN101011354B (zh) 细辛脑亚微乳制剂及其制备方法
CN101961311B (zh) 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
Rawas-Qalaji et al. Sublingual diffusion of epinephrine microcrystals from rapidly disintegrating tablets for the potential first-aid treatment of anaphylaxis: in vitro and ex vivo study
CN114376964B (zh) 一种葛根素纳米粒成膜水凝胶制剂及其制备方法
CN112022919A (zh) 经皮吸收的苍艾油传递体凝胶及其制备方法
CN109481403B (zh) 一种壳聚糖修饰的醋酸曲安奈德脂质体及制备方法
WO2018120920A1 (zh) 一种苯磺顺阿曲库铵冻干粉针制剂
CN108703951B (zh) 改性kgm卵磷脂载nadh透皮醇质体、制剂及其制备工艺与应用
CN105796486A (zh) 丁苯酞脂肪乳注射剂及其制备工艺
CN102988461B (zh) 一种红景天注射液及其制备方法
CN102085186A (zh) 一种甘草次酸乳剂及其制备方法
CN108553412A (zh) 一种含丁苯酞与增溶剂药物组合物
WO2018052185A1 (ko) 사이클로스포린의 안구필름 제형
CN103637985B (zh) 一种稳定的pge1冻干乳及其制备方法
CN109820820B (zh) 一种前列地尔注射液及其制备方法
CN107397745A (zh) 唑类化合物眼用制剂
CN111265477A (zh) 一种卡络磺钠氯化钠注射液及其制备方法
CN100493530C (zh) 一种制备包覆辛夷挥发油纳米脂质体滴鼻剂的方法
CN101940586A (zh) 一种高安全性注射用多烯磷脂酰胆碱及制备方法
CN101147728A (zh) 6-甲氧基双脱氧鸟苷长循环脂质体制剂及制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17889053

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17889053

Country of ref document: EP

Kind code of ref document: A1